DS-1123

DS-1123 is a monoclonal antibody developed by Daiichi Sankyo that acts as an antagonist of fibroblast growth factor receptor 2 (FGFR2), specifically targeting the FGFR2b isoform. It was designed for the treatment of advanced solid tumors, particularly in oncology settings where FGFR2 is implicated in tumor growth and progression. The drug functions by inhibiting FGFR2 signaling pathways, which are involved in cell proliferation and survival in certain cancers. Clinical development reached phase 1 trials for advanced malignant solid neoplasms but has not progressed further or received regulatory approval[1][2][4].